Tranilast

• Background :

  Tranilast is an antiallergic, antifibrotic drug that inhibits collagen synthesis, when administered in a dose –dependent manner for a 48 h treatment (1). As an antifibrotic agent, studies shown an effect on the growth of metastasis of mammary carcinoma. It is associated with the inhibition of the growth factor –beta. (TGF-beta) (2).

• Description :

  Angiogenesis inhibitor

• Product Name Alternative :

  2-{[ (2E) -3- (3,4-dimethoxyphenyl) prop-2- enoyl]amino}benzoic acid

• UNSPSC :

  41116105

• Type :

  Inhibitor

• Source :

  Synthetic

• Field of Research :

  Cell Signaling | Neuroscience | Cancer | Cardiovascular System

• Purity :

  ≥95% (HPLC)

• Weight :

  0.01

• Format :

  Off-white to yellow powder.

• Solubility :

  Soluble in DMSO.

• Molecular Formula :

  C18H17NO5

• Molecular Weight :

  327.33

• Precautions :

  Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only.

• References & Citations :

  1. Yamada H., Tajima S., Nishikawa T., Murad S., and Pinnell S., (1999) The Journal of Biochemistrystry. 116(4): 892-897. 2. Chakrabarti R., Subramanian V., Abadalla J., Jothy S., Predhomme GJ. (2009) Anticancer Drugs. 20(5): 334-45.

• CAS Number :

  53902-12-8